Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

This study has been terminated.
(Poor patient accrual)
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: February 18, 2011
Last updated: September 25, 2014
Last verified: February 2011
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]
    The proportion of postmenopausal breast cancer patients on endocrine therapy who experience grade S1 to S5 alopecia as defined by the Severity of Alopecia Tool (SALT).

Secondary Outcome Measures:
  • Comparison of Tamoxifen, AI or Tamoxifen plus AI [ Time Frame: 1 year ]
    Comparison of the proportion of postmenopausal breast cancer patients treated with Tamoxifen monotherapy, AI monotherapy, or a switch from Tamoxifen to AI who experience alopecia.

  • Severity of Alopecia Tool (SALT) [ Time Frame: 1 year ]
    To identify the severity, or grade, of hair loss experienced by our target population. The severity of alopecia will be represented as a percentage, again in accordance with the SALT.

Estimated Enrollment: 100
Study Start Date: January 2011
Study Completion Date: January 2012
Postmenopausal Women on Endocrine Therapy
Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients that attend Medical Oncology Breast Clinics at Princess Margaret Hospital.

Inclusion Criteria:

  • Postmenopausal women
  • Diagnosed with hormone-receptor positive breast cancer
  • Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole
  • Good command of the English language
  • Under the care of a medical oncologist at Princess Margaret Hospital

Exclusion Criteria:

  • Previously received chemotherapy
  • Recurrent and/or metastatic disease
  • History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01300871

Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 3M9
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Lindsay Carlsson University Health Network-Princess Margaret Hospital
  More Information

Responsible Party: University Health Network, Toronto Identifier: NCT01300871     History of Changes
Other Study ID Numbers: Alopecia
10-0906-CE ( Other Identifier: Research Ethics Board )
Study First Received: February 18, 2011
Last Updated: September 25, 2014

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hair Diseases
Pathological Conditions, Anatomical processed this record on May 23, 2017